SynthesisDrug design, development and therapy2015

Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies.

Runzhe Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.